The Claim
In adults with obesity and prediabetes, administration of liraglutide at 1.8 mg/day significantly increases subjective ratings of fullness and decreases prospective food consumption compared to caloric restriction alone, without resulting in greater reductions in weight loss or fat mass.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity and prediabetes, taking liraglutide at 1.8 mg per day increases feelings of fullness and reduces planned food intake compared to dieting alone, but does not lead to greater loss of body weight or fat mass.
See the scientific wording
In adults with obesity and prediabetes, liraglutide 1.8 mg/day significantly improves subjective ratings of fullness and reduces prospective food consumption compared to caloric restriction, but does not lead to greater weight loss or fat mass reduction.
Liraglutide activates receptors in the brain that signal fullness, making a person feel satisfied without eating less food, so their body does not burn more fat or lose more weight than if they simply ate fewer calories.
What the research says
1 studyLiraglutide made people feel fuller and less hungry, but they didn’t eat less — and they lost less weight and fat than people who just ate fewer calories. So feeling fuller didn’t help them lose more weight.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.